The Food and Drug Administration Oct. 31 said that Ariad Pharmaceuticals, the manufacturer of the leukemia chemotherapy drug Iclusig (ponatinib), has agreed to suspend marketing and sales of Iclusig “because of the risk of life-threatening blood clots and severe narrowing of blood vessels.”
The agency, which requested the halt in marketing and sales, said in a statement, “We will continue to evaluate the drug to further understand its risks and potential patient populations in which the benefits of the drug may outweigh the risks.”
The patients currently receiving Iclusig should discuss with their health-care professionals the risks and benefits of ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.